Morgan Stanley Nautilus Biotechnology, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 406,591 shares of NAUT stock, worth $922,961. This represents 0.0% of its overall portfolio holdings.

Number of Shares

406,591

Previous 440,766 7.75%

Holding current value

$922,961

Previous $1.32 Million 9.26%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.41 - $3.18 $82,361 - $108,676	-34,175 Reduced 7.75%	406,591 $1.2 Million
Q4 2023 Feb 13, 2024	BUY	$2.34 - $3.39 $88,817 - $128,670	37,956 Added 9.42%	440,766 $1.32 Million
Q3 2023 Nov 15, 2023	SELL	$2.87 - $3.94 $55,299 - $75,915	-19,268 Reduced 4.57%	402,810 $1.27 Million
Q2 2023 Aug 14, 2023	BUY	$2.21 - $4.52 $17,450 - $35,689	7,896 Added 1.91%	422,078 $1.63 Million
Q1 2023 May 15, 2023	BUY	$1.67 - $2.77 $71,088 - $117,913	42,568 Added 11.45%	414,182 $1.15 Million

Q4 2022 Feb 14, 2023	BUY	$1.55 - $2.47 $116,806 - $186,136	75,359 Added 25.44%	371,614 $668,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.13 $349,258 - $557,744	178,193 Added 150.93%	296,255 $629,000
Q2 2022 Oct 27, 2022	BUY	$2.64 - $4.84 $176,792 - $324,120	66,967 Added 131.06%	118,062 $318,000
Q2 2022 Aug 15, 2022	BUY	$2.64 - $4.84 $176,792 - $324,120	66,967 Added 131.06%	118,062 $318,000
Q1 2022 Oct 27, 2022	SELL	$3.5 - $5.3 $234,384 - $354,925	-66,967 Reduced 56.72%	51,095 $222,000
Q1 2022 May 13, 2022	BUY	$3.5 - $5.3 $30,324 - $45,919	8,664 Added 20.42%	51,095 $222,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $6.21 $51,953 - $72,501	11,675 Added 37.96%	42,431 $221,000
Q3 2021 Nov 15, 2021	BUY	$6.14 - $10.1 $188,841 - $310,635	30,756 New	30,756 $189,000

Others Institutions Holding NAUT

# of Institutions

Shares Held

63.1M

Call Options Held

14K

Put Options Held

1.8K

View Full List

About Nautilus Biotechnology, Inc.

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $283M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

More about NAUT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account